At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 17 enrolled
Drug / intervention
Stereotactic Body Radiation Therapy (SBRT)combination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RAD 0902: A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
In Brief
A Early Phase 1 clinical trial evaluating Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma (HCC). Completed, enrolled 17 participants across 1 site.
Detailed Summary
This investigational study will evaluate if using a combination of TACE along with high dose SBRT would show improvement in local control in patients with Hepatocellular Carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma (HCC)
CountriesUnited States
Collaborators--
Timeline
Early Ph 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedNov 2010
Primary CompletionSep 2016
Study CompletionDec 2016
TodayJul 2026
First PostedNov 24, 2010
Enrollment StartOct 1, 2010
Primary CompletionSep 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 15.6 years ago
Interventions
Stereotactic Body Radiation Therapy (SBRT)combination
This investigational study will evaluate the combination of TACE along with high dose SBRT. TACE has been used extensively in the palliative treatment of hepatocellular carcinoma (HCC). It will be performed by the Interventional Radiologist prior to radiation therapy.